Sabby Management, LLC Esperion Therapeutics, Inc. Transaction History

Sabby Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$3.34 - $5.56 $3.14 Million - $5.23 Million	-940,400 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.81 - $11.92 $4.52 Million - $11.2 Million	940,400 New	940,400 $4.7 Million
Q1 2019 May 15, 2019	SELL	$40.11 - $53.57 $5.57 Million - $7.44 Million	-138,958 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$36.99 - $59.11 $1.43 Million - $2.28 Million	38,589 Added 38.45%	138,958 $6.39 Million
Q3 2018 Nov 14, 2018	SELL	$40.74 - $51.41 $1.97 Million - $2.48 Million	-48,335 Reduced 32.5%	100,369 $4.45 Million
Q2 2018 Aug 14, 2018	BUY	$36.2 - $76.4 $4.7 Million - $9.92 Million	129,881 Added 690.01%	148,704 $5.83 Million
Q1 2018 May 15, 2018	SELL	$65.94 - $80.76 $8.13 Million - $9.96 Million	-123,362 Reduced 86.76%	18,823 $1.36 Million
Q4 2017 Feb 14, 2018	BUY	$43.47 - $67.43 $2.56 Million - $3.97 Million	58,828 Added 70.57%	142,185 $9.36 Million
Q3 2017 Nov 14, 2017	BUY	$43.8 - $52.77 $3.65 Million - $4.4 Million	83,357	83,357 $4.18 Million

215

129M

1.78M

1.27M

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $112M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sabby Management, LLC with notifications on news.